Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

García-Cabeza, Ignacio; Gómez, Juan-Carlos; Sacristán, Jose A.; Edgell, Eric; De Chavez, Manuel González
January 2001
BMC Psychiatry;2001, Vol. 1, p7
Academic Journal
Background: In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice. Method: Outpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10), and treatment compliance was measured using a physician-rated 4 point categorical scale. Results: A total of 2128 patients initiated treatment (as monotherapy) with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients. Conclusion: Subjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.


Related Articles

  • Safety and Tolerability: How Do Newer Generation “Atypical” Antipsychotics Compare? Tandon, Rajiv // Psychiatric Quarterly;Dec2002, Vol. 73 Issue 4, p297 

    Previously, clinicians worked with antipsychotic drugs that almost invariably caused extrapyramidal side effects (EPS) at the dose at which they were clinically effective. By definition, all newer generation atypical antipsychotic agents are significantly better than conventional agents with...

  • Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder. Gigante, Alexandre Dnarte; Lafer, Beny; Yatham, Lakshmi N. // CNS Drugs;2012, Vol. 26 Issue 5, p403 

    Depot antipsychotics have been used as a strategy to reduce non-adherence to medications in schizophrenia and bipolar disorder (BD). This article reviews the literature on the efficacy and safety of first- and second-generation depot antipsychotics (FGDA and SGDA, respectively) for the...

  • Practical Issues with Amisulpride in the Management of Patients with Schizophrenia. Pani, Luca; Villagrán, José M.; Kontaxakis, Vassilis P.; Alptekin, Köksal // Clinical Drug Investigation;2008, Vol. 28 Issue 8, p466 

    Amisulpride is an atypical antipsychotic with a significantly greater effect size than first-generation, typical antipsychotics, and efficacy at least similar to that of olanzapine and risperidone in large-scale clinical trials in schizophrenia. Amisulpride provides greater improvement in...

  • Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia. Barteček, Richard; Kašpárek, Tomáš; Češková, Eva // Central European Journal of Medicine;Oct2011, Vol. 6 Issue 5, p662 

    Withdrawal-emergent adverse effects of antipsychotics are an infrequently identified condition which can appear during antipsychotic dose reduction and medication change. In this paper, we present the case of severe extrapyramidal symptoms after a dose reduction of risperidone is presented. A...

  • Olanzapine.  // Reactions Weekly;12/8/2007, Issue 1181, p28 

    The article describes the case of a teenage boy who developed blepharoclonus during treatment with olanzapine for schizophrenia. He had previously been treated with risperidone and quetiapine. He was hospitalized for three months and started receiving haloperidol. He was treated with artificial...

  • Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Riedel, Michael; Müller, Norbert; Strassnig, Martin; Spellmann, Ilja; Engel, Rolf R.; Musil, Richard; Dehning, Sandra; Douhet, Anette; Schwarz, Markus J.; Möller, Hans-Jürgen // European Archives of Psychiatry & Clinical Neuroscience;2005, Vol. 255 Issue 6, p432 

    Atypical antipsychotics are generally thought to be more effective than conventional agents in treating the negative symptoms of schizophrenia; however, there have been few direct comparisons among atypicals. We therefore investigated risperidone and quetiapine with respect to their efficacy...

  • Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Tiwari, A. K.; Deshpande, S. N.; Lerer, B.; Nimgaonkar, V. L.; Thelma, B. K. // Pharmacogenomics Journal;2007, Vol. 7 Issue 5, p305 

    Tardive dyskinesia (TD) is an iatrogenic disorder observed in ∼20–30% of schizophrenia patients on long-term treatment with typical antipsychotic drugs. CYP1A2 is involved in the metabolism of atypical antipsychotic drugs such as clozapine and olanzapine. It is not directly involved...

  • A Critical Review of Atypical Antipsychotic Utilization: Comparing Monotherapy with Polypharmacy and Augmentation. Stahl, S. M.; Grady, M. M. // Current Medicinal Chemistry;Feb2004, Vol. 11 Issue 3, p313 

    The atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms. However, these agents, like other...

  • Newer Antipsychotic Drugs Appear to Stem Violent Behavior.  // Ascribe Newswire: Medicine;4/16/2004, p35 

    Researchers at Duke University Medical Center have found that a new generation of medications called atypical antipsychotics can significantly lower the risk of violent behavior in people with schizophrenia who are being treated in community-based centers. The study is the first to examine the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics